Dr Ian Fry BSc, MSc, PhD, EuroClinChem. FRCPath, MBE has worked in the NHS for over 42 years and was awarded an MBE for services to Medicine in 2009. He has worked at executive and board level for over 15 years, having experience in both the private and public sector. He is involved at the national and local level in the reorganisation of pathology services in England and Wales. He has undertaken a wide range of consultancy work leading on consolidation, transformation and integration of pathology services across different acute hospital trusts. In 2018 he was ranked in the top 100 most influential and inspirational leaders in laboratory medicine globally by the Pathologist Journal. He retired four years ago as Managing Director of Berkshire and Surrey Pathology Services, a contractual joint venture pathology network of five acute hospitals undertaking 42 million tests per annum but he continues to be active:
-A member of the NHS National Pathology Stakeholder Board as a specialist advisor. This board provides direction, expert opinion and strategic overview to the National Pathology Transformation Project.
– An advisor in 2020/21 within DHSC supporting the national COVID pandemic programme
-Non executive advisory role within Berkshire and Surrey Pathology Service specifically relating to: the implementation of innovative technology (AI, digitalisation, genomics, online testing) and key transformation projects to help improve efficiency and develop the workforce.
-Undertaking advisory/consultancy work more widely on strategy, operational efficiency and customer relations both in the public and private sector for pathology.
During his career he has led radical service redesign and development of the workforce across complex environments during significant change primarily driven by advances in medical science and technology. It is in this context that he is supporting Berkshire and Surrey Pathology Services which is both a PathLAKE partner and currently implementing full digitalisation.
